Tractenberg Rochelle E, Weiner Myron F, Patterson Marian B, Teri Linda, Thal Leon J
Center for Population and Health, Georgetown University, Washington, DC 20057-1197, USA.
J Geriatr Psychiatry Neurol. 2003 Jun;16(2):94-9. doi: 10.1177/0891988703016002006.
In this post hoc analysis of baseline responses to the CERAD Behavior Rating Scale for Dementia in a clinical trial of interventions for agitation in Alzheimer's disease (AD), the authors investigated the distribution of, and relationships between, agitation, depression, and psychosis in 148 individuals with AD. Prevalence of depressive symptoms was highest (78.4%), followed by agitation (77.6%) and psychotic symptoms (69.3%); 51.1% of the sample had symptoms in all 3 domains. Cross-sectionally, psychotic symptoms were most closely associated with Mini-Mental State Examination (MMSE) scores, while agitation was less so. Depressive symptoms were relatively consistently prevalent across MMSE levels. After controlling for the presence of agitated symptoms, psychosis and depression were significantly associated, but neither symptoms of psychosis nor of depression were associated with agitation when depression or psychosis, respectively, was controlled for. Significant psychopathological comorbidity should be considered in the design of clinical trials targeting particular psychopathology in this disease population.
在一项针对阿尔茨海默病（AD）激越症状干预的临床试验中，对痴呆症的CERAD行为评定量表的基线反应进行的这项事后分析中，作者调查了148例AD患者中激越、抑郁和精神病症状的分布情况及其相互关系。抑郁症状的患病率最高（78.4%），其次是激越（77.6%）和精神病症状（69.3%）；51.1%的样本在所有三个领域都有症状。从横断面来看，精神病症状与简易精神状态检查表（MMSE）评分关联最为密切，而激越症状的关联程度则较弱。抑郁症状在不同MMSE水平上的患病率相对稳定。在控制了激越症状的存在后，精神病和抑郁显著相关，但在分别控制抑郁或精神病时，精神病症状和抑郁症状均与激越无关。在针对该疾病人群特定精神病理学设计临床试验时，应考虑显著的精神病理共病情况。
